Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| R01NR010004 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institutes of Health (NIH) | NIH |
| National Institute of Nursing Research (NINR) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to test the effects of different persuasive informational messages on rates of rapid HIV testing and willingness to participate in a HIV vaccine clinical trial. Adult African-American, non-Latina White, and Latina women will be recruited. Women will initially be randomized to 4 groups: 1. no message control; 2. 1-sided message that mentions benefits of HIV testing; 3. 2-sided message that acknowledges minor opposition to testing, then refutes the opposition; and 4. 2-sided message that acknowledge stronger opposition to testing, then refutes the opposition. Women will be offered HIV testing, then re-randomized to a similar set of 4 messages related to HIV vaccine trials. There will therefore be 16 groups in total (4 X 4).
This 5-year proposal responds to PAS-03-168, "Enrolling Women and Minorities in HIV/AIDS Research Trials." This study seeks to evaluate persuasive message interventions to increase HIV testing rates and improve acceptability of participation in a phase 3 HIV vaccine clinical trial among African-American, Latina, and White women. We plan to evaluate 1-sided messages, which mention only the benefits of an action, versus 2-sided messages, which mention negative aspects of the action, followed by positive counterarguments. The Health Belief Model, Inoculation and Attribution Theories will guide the research. Participants will be women attending urban community health clinics in Indianapolis, IN. Specific Aim 1 is to identify obstacles to HIV testing and to participation in a HIV vaccine clinical trial. This aim will be accomplished in years 1 and 2 through individual semi-structured interviews. We will analyze data via thematic content analysis and will use interview findings to assist in the development of measures and interventions employed in the intervention phase (years 3-5). Specific Aim 2 is to evaluate the effects of 2-sided versus 1-sided persuasive messages on rates of acceptance of rapid HIV testing. Demographic, behavioral, and attitudinal measures will be administered via audio computer-assisted self-interview (A-CASI). Participants will be randomized to the intervention groups via A-CASI as well. The outcome will be acceptance/rejection of free rapid HIV testing. This Aim will be evaluated via binary logistic regression. Specific Aim 3 is to evaluate the effects of 2-sided versus 1-sided messages on willingness to participate in phase 3 clinical trials for a preventive HIV vaccine. Participants will complete this 2nd A-CASI survey and will again be randomized to intervention groups. The outcome will be a scale measuring acceptability of clinical trial participation. This Aim will be evaluated via one-way Analysis of Variance. This study is relevant to public health in that the results may help us to understand how to improve enrollment of women and minorities into preventive HIV vaccine clinical trials and how to encourage women and minorities to get tested for HIV.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1. Control PLUS Control | No Intervention | ||
| Arm 2. Control PLUS 1-Sided | Experimental | No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation. |
|
| Arm 3. Control PLUS 2-Sided Trivial | Experimental | No message intervention control condition regarding HIV testing AND 2-Sided trivial message experimental intervention condition regarding HIV vaccine clinical trial participation. |
|
| Arm 4. Control PLUS 2-Sided Major | Experimental | No message intervention control condition regarding HIV testing AND 2-Sided Major message experimental intervention condition regarding HIV vaccine clinical trial participation. |
|
| Arm 5. 1-Sided PLUS Control | Experimental | 1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Message Sidedness | Behavioral | There are 16 pairs of messages varying in sidedness. Arm 1 is a no message control condition regarding HIV testing + a no message control condition regarding trial participation. Arm 2 is control + a 1-sided message. Arm 3 is control + a trivial 2-sided message. Arm 4 is control + a major 2-sided message. Arm 5 is a 1-sided message + a control. Arm 6 is a 1-sided message + a 1-sided message. Arm 7 is a 1-sided message + a trivial 2-sided message. Arm 8 is a 1-sided message + a major2-sided message. Arm 9 is a trivial 2-sided message + a control. Arm 10 is a trivial 2-sided message + a 1-sided message. Arm 11 is a trivial 2-sided message + a trivial 2-sided message. Arm 12 is a trivial 2-sided message + a major 2-sided message. Arm 13 is a major 2-sided message + a control. Arm 14 is a major 2-sided message + a 1-sided message. Arm 15 is a major 2-sided message + a trivial 2-sided message. Arm 16 is a major 2-sided message + a major2-sided message. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants Who Accepted Rapid HIV Testing. | Acceptance of rapid HIV testing. Acceptance was assessed by actual administration of rapid oral HIV test by research staff. | During study visit. At approximately 30 minutes into the study visit. After part 1 of the questionnaire was completed. |
| Willingness to Participate in a HIV Vaccine Clinical Trial | Willingness to Participate in a HIV Vaccine Clinical Trial. Assessed via participant self-report with 6 items on Part 2 of the questionnaire. Item responses measured on 5-point Likert-type scale ranging from Strongly Disagree (value = 1) to Strongly Agree (value = 5). | Approximately 60 minutes into the study visit, at the end of Part 2 of the questionnaire. |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gregory D Zimet, PhD | Indiana University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Indiana University Medical Group Clinics | Indianapolis | Indiana | 46202 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 18191770 | Result | Burrage JW, Zimet GD, Cox DS, Cox AD, Mays RM, Fife RS, Fife KH. The Centers for Disease Control and Prevention revised recommendations for HIV testing: reactions of women attending community health clinics. J Assoc Nurses AIDS Care. 2008 Jan-Feb;19(1):66-74. doi: 10.1016/j.jana.2007.11.003. | |
| 25374047 | Derived | Kasting ML, Cox AD, Cox D, Fife KH, Katz BP, Zimet GD. The effects of HIV testing advocacy messages on test acceptance: a randomized clinical trial. BMC Med. 2014 Nov 6;12:204. doi: 10.1186/s12916-014-0204-4. |
Not provided
Not provided
Message intervention details are in the Brief Summary
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | HIV TEST MSG Control/ VACCINE TRIAL MSG Control | No message intervention control condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. |
| FG001 | HIV TEST MSG Control/ VACCINE TRIAL MSG 1-Sided | No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| FG002 | HIV TEST MSG Control/ VACCINE TRIAL MSG 2-Sided Trivial | No message intervention control condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| FG003 | HIV TEST MSG Control/ VACCINE TRIAL MSG 2-Sided Major | No message intervention control condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| FG004 | HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG Control | 1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. |
| FG005 | HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 1-Sided | 1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| FG006 | HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 2-Sided Trivial | 1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| FG007 | HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 2-Sided Major | 1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| FG008 | HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG Control | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. |
| FG009 | HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 1-Sided | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| FG010 | HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 2-Sided Trivia | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| FG011 | HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 2-Sided Major | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| FG012 | HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG Control | 2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. |
| FG013 | HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 1-Sided | 2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| FG014 | HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 2-Sided Trivial | 2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| FG015 | HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 2-Sided Major | 2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | HIV TEST MSG Control/ VACCINE TRIAL MSG Control | No message intervention control condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. |
| BG001 | HIV TEST MSG Control/ VACCINE TRIAL MSG 1-Sided |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Number of Participants Who Accepted Rapid HIV Testing. | Acceptance of rapid HIV testing. Acceptance was assessed by actual administration of rapid oral HIV test by research staff. | Posted | Number | participants | During study visit. At approximately 30 minutes into the study visit. After part 1 of the questionnaire was completed. |
|
Not provided
Adverse events were not collected.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | HIV TEST MSG Control/ VACCINE TRIAL MSG Control | No message intervention control condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Gregory D Zimet | Indiana University | 317-274-8812 | gzimet@iupui.edu |
Not provided
Not provided
Not provided
Not provided
Not provided
| Arm 6. 1-Sided PLUS 1-Sided | Experimental | 1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation. |
|
| Arm 7. 1-Sided PLUS 2-Sided Trivial | Experimental | 1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Trivial message intervention experimental condition regarding HIV vaccine clinical trial participation. |
|
| Aim 8. 1-Sided PLUS 2-Sided Major | Experimental | 1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Major message intervention experimental condition regarding HIV vaccine clinical trial participation. |
|
| Arm 9. 2-Sided Trivial PLUS Control | Experimental | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. |
|
| Arm 10. 2-Sided Trivial PLUS 1-Sided | Experimental | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation. |
|
| Arm 11. 2-Sided Trivial PLUS 2-Sided Trivial | Experimental | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation. |
|
| Arm 12. 2-Sided Trivial PLUS 2-Sided Major | Experimental | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation. |
|
| Arm 13. 2-Sided Major PLUS Control | Experimental | 2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. |
|
| Arm 14. 2-Sided Major PLUS 1-Sided | Experimental | 2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation. |
|
| Arm 15. 2-Sided Major PLUS 2-Sided Trivial | Experimental | 2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation. |
|
| Arm 16. 2-Sided Major PLUS 2-Sided Major | Experimental | 2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation. |
|
|
No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| BG002 | HIV TEST MSG Control/ VACCINE TRIAL MSG 2-Sided Trivial | No message intervention control condition regarding HIV testing AND 2-Sided trivial message experimental intervention condition regarding HIV vaccine clinical trial participation. |
| BG003 | HIV TEST MSG Control/ VACCINE TRIAL MSG 2-Sided Major | No message intervention control condition regarding HIV testing AND 2-Sided Major message experimental intervention condition regarding HIV vaccine clinical trial participation. |
| BG004 | HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG Control | 1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. |
| BG005 | HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 1-Sided | 1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| BG006 | HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 2-Sided Trivial | 1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Trivial message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| BG007 | HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 2-Sided Major | 1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Major message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| BG008 | HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG Control | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. |
| BG009 | HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 1-Sided | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| BG010 | HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 2-Sided Trivia | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| BG011 | HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 2-Sided Major | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| BG012 | HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG Control | 2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. |
| BG013 | HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 1-Sided | 2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| BG014 | HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 2-Sided Trivial | 2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| BG015 | HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 2-Sided Major | 2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation. |
| BG016 | Total | Total of all reporting groups |
| Participants |
|
| Age Continuous | Mean | Standard Deviation | years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG002 | 2-Sided Trivial | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. |
| OG003 | 2-Sided Major | 2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. |
|
|
|
| Primary | Willingness to Participate in a HIV Vaccine Clinical Trial | Willingness to Participate in a HIV Vaccine Clinical Trial. Assessed via participant self-report with 6 items on Part 2 of the questionnaire. Item responses measured on 5-point Likert-type scale ranging from Strongly Disagree (value = 1) to Strongly Agree (value = 5). | Only participants who answered the Willingness to Participate questions on the survey were included in these analyses. | Posted | Mean | Standard Deviation | units on a scale | Approximately 60 minutes into the study visit, at the end of Part 2 of the questionnaire. |
|
|
|
|
| 0 |
| 0 |
| 0 |
| 0 |
| EG001 | HIV TEST MSG Control/ VACCINE TRIAL MSG 1-Sided | No message intervention control condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation. | 0 | 0 | 0 | 0 |
| EG002 | HIV TEST MSG Control/ VACCINE TRIAL MSG 2-Sided Trivial | No message intervention control condition regarding HIV testing AND 2-Sided trivial message experimental intervention condition regarding HIV vaccine clinical trial participation. | 0 | 0 | 0 | 0 |
| EG003 | HIV TEST MSG Control/ VACCINE TRIAL MSG 2-Sided Major | No message intervention control condition regarding HIV testing AND 2-Sided Major message experimental intervention condition regarding HIV vaccine clinical trial participation. | 0 | 0 | 0 | 0 |
| EG004 | HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG Control | 1-Sided message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. | 0 | 0 | 0 | 0 |
| EG005 | HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 1-Sided | 1-Sided message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation. | 0 | 0 | 0 | 0 |
| EG006 | HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 2-Sided Trivial | 1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Trivial message intervention experimental condition regarding HIV vaccine clinical trial participation. | 0 | 0 | 0 | 0 |
| EG007 | HIV TEST MSG 1-Sided/ VACCINE TRIAL MSG 2-Sided Major | 1-Sided message intervention experimental condition regarding HIV testing AND 2-Sided Major message intervention experimental condition regarding HIV vaccine clinical trial participation. | 0 | 0 | 0 | 0 |
| EG008 | HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG Control | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. | 0 | 0 | 0 | 0 |
| EG009 | HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 1-Sided | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation. | 0 | 0 | 0 | 0 |
| EG010 | HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 2-Sided Trivia | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation. | 0 | 0 | 0 | 0 |
| EG011 | HIV TEST MSG 2-Sided Trivial/ VACCINE TRIAL MSG 2-Sided Major | 2-Sided Trivial message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation. | 0 | 0 | 0 | 0 |
| EG012 | HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG Control | 2-Sided major message intervention experimental condition regarding HIV testing AND No message intervention control condition regarding HIV vaccine clinical trial participation. | 0 | 0 | 0 | 0 |
| EG013 | HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 1-Sided | 2-Sided major message intervention experimental condition regarding HIV testing AND 1-Sided message intervention experimental condition regarding HIV vaccine clinical trial participation. | 0 | 0 | 0 | 0 |
| EG014 | HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 2-Sided Trivial | 2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided trivial message intervention experimental condition regarding HIV vaccine clinical trial participation. | 0 | 0 | 0 | 0 |
| EG015 | HIV TEST MSG 2-Sided Major/ VACCINE TRIAL MSG 2-Sided Major | 2-Sided major message intervention experimental condition regarding HIV testing AND 2-Sided major message intervention experimental condition regarding HIV vaccine clinical trial participation. | 0 | 0 | 0 | 0 |
Not provided
Not provided
|
One-Way Analysis of Variance |
| ANOVA |
degrees of freedom = (1,1028) |
| <.25 |
| Marginal Means |
| 2.51 |
| Standard Error of the Mean |
| .036 |
| 2-Sided |
| 95 |
| 2.44 |
| 2.58 |
There was no significant effect for the 2-sided trivial message compared to the control group on Willingness to Participate in an HIV vaccine clinical trial. |
| No |
| Superiority or Other |
| One-Way Analysis of Variance | ANOVA | <.91 | Marginal Means | 2.47 | Standard Error of the Mean | .036 | 2-Sided | 95 | 2.40 | 2.54 | There was no significant effect for the 2-sided major message compared to the control group on Willingness to Participate in an HIV vaccine clinical trial. | No | Superiority or Other |